PARP inhibitor combination therapy.
Loading...
Embargo End Date
ICR Authors
Authors
Dréan, A
Lord, CJ
Ashworth, A
Lord, CJ
Ashworth, A
Document Type
Journal Article
Date
2016-12-01
Date Accepted
2016-10-26
Abstract
In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.
Citation
Critical reviews in oncology/hematology, 2016, 108 pp. 73 - 85
Source Title
Publisher
ELSEVIER SCIENCE INC
ISSN
1040-8428
eISSN
1879-0461
Collections
Research Team
Gene Function